Skip to main content

ARMP

Stock
Health Care
Biotechnology

Performance overview

ARMP Price
Price Chart

Forward-looking statistics

Beta
0.22
Risk
76.10%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Company info

SectorHealth Care
IndustryBiotechnology
Employees70
Market cap$98.3M

Fundamentals

Enterprise value$191.7M
Revenue$4.7M
Revenue per employee—
Profit margin-9.07%
Debt to equity-2.50

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.40
Dividend per share—
Revenue per share$0.13
Avg trading volume (30 day)$85K
Avg trading volume (10 day)$50K
Put-call ratio—

Macro factor sensitivity

Growth-5.2
Credit+11.8
Liquidity+1.4
Inflation-8.0
Commodities+0.4
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-1.38
Price to sales16.71
P/E Ratio-1.38
Enterprise Value to Revenue40.80
Price to book-1.46

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

Zacks Investment Research (May 21, 2025)
Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets.

Benzinga (January 30, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free